A new study co-authored by CU Cancer Center Member James Costello, PhD, identifies NPEPPS as a key gene that limits the uptake of cisplatin, a widely used chemotherapy drug, into tumor cells. By inhibiting NPEPPS, researchers can enhance cisplatin’s effectiveness, offering a promising strategy to overcome tumor resistance and improve outcomes for patients with treatment-resistant cancers.